ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ORKA vs CLDX // EV/EBITDA & P/E VALUATION

Oruka Therapeutics Inc. (NASDAQ) VS. Celldex Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ORKA 9 — CLDX 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ORKA VS. CLDX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ORKA CLDX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 87.10% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -18.80% -35.00% +16.20 ORKA /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -1.38% -9.10% +7.72 ORKA /fcf-yield <GO>
Operating Margin -6.80% -60.00% +53.20 ORKA /operating-margins <GO>
Net Profit Margin -5.90% -60.00% +54.10 ORKA /net-margins <GO>
Revenue Growth (YoY) -4.40% -65.00% +60.60 ORKA /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 26.00 20.25 +5.75 ORKA /balance-sheet <GO>
Piotroski F-Score Quality 4/9 3/9 +1.00 ORKA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 66.7 45.5 +21.25 ORKA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.13 — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 28.0x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $6.40B $2.35B $4.05B ORKA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ORKA REV CLDX REV ORKA GROSS % CLDX GROSS % ORKA FCF CLDX FCF
FY 2025 $0 $1.5M — 87.1% -$88.4M -$213.7M
FY 2024 $0 $7.0M — 97.2% -$58.0M -$159.7M
FY 2023 $0 $6.9M — — -$5.0M -$107.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ORKA // BETA 1.13
CLDX // BETA —